The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes.
Dyslipidemia and hyperglycemia are common among patients presenting with acute coronary syndromes (ACS), and patients with ACS and metabolic disorders are at increased risk for worse outcomes. Although guidelines for the diagnosis and management of dyslipidemia, diabetes, and the metabolic syndrome have been published, these guidelines have not specifically focused on the ACS patient population. Recent observational registries and clinical trials have advanced the appreciation of these disorders in ACS populations and data from these studies support aggressive efforts to diagnose and treat dyslipidemia and hyperglycemia in patients admitted for ACS.
Goyal
Abhinav
A
Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA.
Petersen
John L
JL
Mahaffey
Kenneth W
KW
D002986:Clinical Trials as Topic; D015897:Comorbidity; D003925:Diabetic Angiopathies / Q000175:diagnosis; D018149:Glucose Intolerance / Q000175:diagnosis; D005951:Glucose Tolerance Test; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000453:epidemiology; D009203:Myocardial Infarction / Q000453:epidemiology* / Q000503:physiopathology*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors